BioPharma Dive

Kaos Capital wants a “governance reset” to alter the Duchenne cell therapy maker’s strategic course. Elsewhere, Bristol Myers furthered efforts to build an “AI-powered” discovery engine.

As Eli Lilly and Novo Nordisk race for share, surveys show affordability and prescribing preferences may help decide the winners.

Pasatru’s approval sets up a market battle in a rare indication where the only available treatment has generated disappointing sales.

Moderna gained $45 billion in market value in a single day, a surge that brought the company’s stock to levels not seen since 2024 — and saddled it with expectations that may be tough to meet. 

The clearance of Genglycos for a rare glycogen storage disease gives Ultragenyx a sellable voucher and momentum ahead of an eagerly anticipated study readout.

Heidi Overton, a medical doctor and veteran of the America First think tank, currently serves as deputy director of the White House Domestic Policy Council.

At an interim data check, investigators of a key trial found the individualized mRNA treatment kept disease from returning and stopped its spread, sparking a surge in Moderna shares.

The Alesta buyout helps restock BioMarin's pipeline with an asset it says could “reach our largest addressable patient population,” joining other muscle and skeletal disease treatments in development.

A combination of AstraZeneca’s Tagrisso and Hutchmed’s Orpathys extended survival for some lung cancer patients. Elsewhere, MapLight floated the idea of partnering on its autism drug.

Tanabe Pharma has already asked the FDA to approve the medicine for two conditions that cause severe reactions to sunlight.

The clearance of Zenbexus is the first for a group of protein-degrading “CELMoD” medicines that could help Bristol Myers rejuvenate a key drug franchise.

The FDA is “willing to review” an updated submission for Capricor’s Duchenne cell therapy, its CEO said. Elsewhere, a heart drug battle spilled into court and Rigel priced the first “Protac” medicine.

New government funding from Pennsylvania to Kansas City is strengthening biotech hubs — but experts say money alone won’t determine where pharma builds next.

The findings position their drug, zipalertinib, as a threat to multiple approved medicines — while setting a bar for others in testing.

Wall Street analysts view the deal as a risky, high-reward bet on a treatment that’s nearing a possible regulatory approval and could be superior to existing medications.

Ahead of an approval filing, the drugmaker is amping up a fight against sellers who claim to offer versions of its highly anticipated “triple-G” weight loss medicine.

Results from a late-stage study focused on generalized anxiety disorder were a “clean win” to analysts, who believe Definium has a drug with multibillion-dollar sales potential.

Some analysts believe Silence’s polycythemia vera drug could be superior to a closely watched Takeda medicine. Elsewhere, the FDA spurned a radiopharmaceutical and AbCellera shares climbed to levels not seen since 2023.

Co-founded by pioneering researcher Georg Schett and ex-Sanofi CSO Frank Nestle, the startup is advancing a trio of multifaceted antibodies with the potential to treat several immune diseases.

Ying Huang is now running K2 Therapeutics, which has licensed multiple prospects from China-based biotechs and is searching for more “high-potential” medicines.